TJO-087 is under clinical development by TaeJoon Pharmaceuticals and currently in Phase III for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase III drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how TJO-087’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TJO-087 (cyclosporine) is under development for the treatment of dry eye syndrome. The drug candidate is administered topically as eye drops and it acts by targeting calcineurin.
TaeJoon Pharmaceuticals overview
TaeJoon Pharmaceuticals (Taejoon) is a pharmaceutical company that markets ophthalmic agents and other drugs. It offers products in the form of injections, powders, eye drops, spray, syrups, tablets, soft capsules, liquids for external use, and hard capsules. The company’s powder products comprise of coolprep powder, polyethylen glycol, and colyte powder products. Taejoon’s products are used in ophthalmological, laxative, gastrointestinal, and contrast media applications. It sells products through a network of distributors in South Korea, Thailand, Germany, Russia, the UK and the US. The company operates in Seoul, Gunpo, Daejeon, Daegu, Gwangju and Busan, South Korea. Taejoon is headquartered in Seoul, South Korea.
For a complete picture of TJO-087’s drug-specific PTSR and LoA scores, buy the report here.